Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

Sponsor
Aline Fusco Fares, MD
Study ID
NCT06667154
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lung Cancer, Nonsmall Cell
  • Non-Small Cell Lung Cancer NSCLC

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.

Key Dates

Start date
Oct 10, 2023
Status verified
Oct 2024
Primary completion
Oct 31, 2025
Completion
Oct 31, 2027

Study Design

Enrollment
33 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Low-dose nivolumab combined with platinum-based doublet chemotherapy

Primary Outcome Measure

Major Pathologic Response [ Time Frame: 2-3 months ]

Central Contacts

Related Studies